The Japan Pharmaceutical Market Report is Segmented by Therapeutic Category (Antiallergics, Blood and Blood-Forming Organs, Cardiovascular System, Dermatologicals, Genito Urinary System, Respiratory System, Sensory Organs, and Other Therapeutic Categories) and Prescription Type (Prescription Drugs (Branded Drugs and Generic Drugs) and OTC). The Market Size and Forecasts are Provided in Terms of Value (USD) for the Above Segments.

The statistic depicts the market size of the pharmaceutical industry in Japan from 2008 to 2015. In 2015, the Japanese pharmaceutical market was valued at approximately 10.3 trillion Japanese yen, up from around 9.6 trillion yen in the previous year.

The size of the Japan Pharmaceutical Industry market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 0.88% during the forecast period.Japan Pharmaceutical Industry, among other things, is one of the most mature in the world and always has products of good quality and stringent norms, especially about latest research and developments. The industry significantly benefits health on a global level through creation and manufacture of latest medications and medical equipment.They have a high level of capability in various therapeutic areas including oncology, gastroenterology, neurology, and cardiovascular disease. Japanese firms have a good history of developing innovative treatments and therapies, often leading the industry benchmarking. The regulatory regime in Japan is also more robust, hence ensuring drugs are safe and effective to be used.It is innovating and adapting to the challenges posed by aging demographics and rising healthcare costs.Japanese pharmaceutical companies are growing rapidly around the world, forming strategic alliances and conducting research and development, so they do not fall behind. Recent developments include: In April 2022, Takeda pharmaceuticals received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine for primary and booster immunization in individuals aged 18 and older., In March 2022, Chugai Pharmaceutical Co. Ltd obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan for Vabysmo for Intravitreal Injection 120 mg/ mL (generic name: farcical), an anti-VEGF/anti-Ang-2 bispecific antibody for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema (DME).. Key drivers for this market are: Rising Geriatric Population and Increasing Burden of Chronic Diseases, Increasing Research and Development Activities Along with Growing R&D Investments. Potential restraints include: Stringent Regulatory Scenario. Notable trends are: Prescription Drugs Segment is Expected to Hold a Significant Share in the Market Over Forecast Period.

The statistic displays the market size of therapeutic agents for osteoporosis in Japan in 2014 and 2016 with a forecast for 2024. In 2016, the source evaluated the market size to reach approximately 2.6 trillion Japanese yen. This figure was estimated to increase to around 3.8 trillion yen in 2024.

Japan pharmaceutical 3PL market size reached USD 5.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.2 Billion by 2033, exhibiting a growth rate (CAGR) of 10.26% during 2025-2033. The increasing focus of pharmaceutical companies on their core competencies, like drug development and research, without being encumbered by the intricate demands of distribution and compliance, is primarily driving the market growth.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on service and temperature control.

Japan pharmaceutical filtration market size reached USD 812.3 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,382.6 Million by 2033, exhibiting a growth rate (CAGR) of 12.07% during 2025-2033. The implementation of stringent regulations by government bodies to ensure purity in the production of pharmaceuticals products is primarily driving the market growth.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on product, technique, application, and scale of operation.

Japan Pharmaceutical Market is anticipated to grow with an impressive CAGR in the forecast period, FY2023-FY2027. Japan Pharmaceutical Market Size, Share, Growth, Trend & Pharmaceutical Market Forecast 2027 By Drug Type, By Product Type, By Application, By Distribution Channel, By Region, Competition Forecast & Opportunities, FY2027

Takeda pharmaceutical company limited ranked first as a distributor among pharmaceutical companies in Japan in terms of prescription drug sales in 2022, reaching around 746.5 billion Japanese yen. That year, Takeda stood second at the promotion company level, with more than 503 billion yen in sales.

The Report Covers Japan Pharmaceutical 3PL Companies and it is segmented by service (domestic transportation management, international transportation management, and value-added warehousing and distribution) and by temperature control (controlled/cold chain logistics vs. non-controlled/non-cold chain logistics). The report offers market size and forecasts for the Japan pharmaceutical 3PL market in terms of value (USD million) for all the above segments.

Forecast: Pharmaceutical Industry Export Market Share in Japan 2023 - 2027 Discover more data with ReportLinker!

Pharmaceuticals in Dosage Market Size Value Per Capita in Japan, 2021 Discover more data with ReportLinker!

Snapshot img

Bio-pharma Market Size 2024-2028

The bio-pharma market size is forecast to increase by USD 204.09 billion at a CAGR of 7.98% between 2023 and 2028.

The market is experiencing significant growth driven by the increasing prevalence of health disorders and the rise in the production of vaccines. The global population is aging, leading to an increase in chronic diseases such as cancer, type 2 diabetes, and cardiovascular diseases. This trend is particularly prominent in developed markets like the US, where an aging population and rising healthcare costs are fueling demand for innovative and effective bio-pharmaceutical solutions. Another key driver for the market is the production of vaccines, which has gained significant momentum in recent years due to the ongoing COVID-19 pandemic.
The rapid development and distribution of vaccines have highlighted the critical role of the bio-pharma industry in addressing global health crises. However, the high cost of bio-pharmaceuticals remains a significant challenge for market growth. This issue is compounded by regulatory requirements and lengthy approval processes, which can delay the entry of new products and limit competition. To capitalize on market opportunities and navigate challenges effectively, companies in the market must focus on innovation, cost reduction, and regulatory compliance. Strategic partnerships, collaborations, and acquisitions can help companies leverage each other's strengths and resources to bring new products to market more quickly and cost-effectively.

What will be the Size of the Bio-pharma Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of therapeutic modalities, including monoclonal antibodies, recombinant growth factors, purified proteins, recombinant enzymes, vaccines, recombinant hormones, cell therapies, gene therapies, synthetic immunomodulators, and various other living organisms derived from bacteria, yeast, and mammalian cells. Biotechnological processes are employed to produce these complex molecules, which target specific biological pathways, receptors, and molecular structures. Biopharmaceuticals address a broad spectrum of diseases, such as cancer, diabetes, psoriasis, rheumatoid arthritis, genetic mutations, and various other conditions.
Personalized medicine and the identification of biomarkers have significantly influenced the market's growth trajectory. The market's size and direction reflect the ongoing advancements in technology and the increasing demand for innovative therapeutic solutions.

How is the Bio-pharma Industry segmented?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Monoclonal antibodies
  Recombinant growth factors
  Vaccines
  Recombinant hormones
  Others


Application

  Oncology
  Autoimmune disorder
  Metabolic disorder
  Hormonal disorder
  Others


Geography

  North America

    US


  Europe

    France
    Germany


  Asia
  Rest of World (ROW)

By Product Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period. Monoclonal antibodies represent a significant segment of the market due to their high price point and life-saving capabilities, despite lower sales volumes compared to other pharmaceuticals. Revenues from monoclonal antibodies are substantial, making them a valuable contribution to the industry. The monoclonal antibodies segment is projected to grow during the forecast period, with companies investing heavily in research and development (R&D) of biologic drugs. Monoclonal antibodies hold the largest share in this area, as companies focus on expanding their bio-pharmaceutical domains.

Key therapeutic areas for monoclonal antibodies include oncology, autoimmune disorders, metabolic disorders, hormonal disorders, cardiovascular diseases, neurological diseases, and chronic conditions such as dementia and Alzheimer's disease. Technologies such as high throughput screening, combinatorial chemistry, computational modeling, genomics, next-generation sequencing, gene editing techniques, and purified proteins are essential in the development and production of monoclonal antibodies and other biopharmaceuticals.

Get a glance at the market report of share of various segments Request Free Sample

The Monoclonal antibodies segment was valued at USD 151.68 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights

In 2023, the value of pharmaceutical drug imports to Japan amounted to around 3.8 trillion Japanese yen, representing an increase from approximately 3.6 trillion yen in the previous year.  Japan’s domestic pharma market Prescription pharmaceuticals make up more than 90 percent of Japan’s local medical market, reaching over eight trillion Japanese yen in production value, including pharmaceuticals such as antineoplastics, cardiovascular agents, and agents affecting metabolism. Most of Japan’s top ten pharmaceutical producers are local manufacturers, with companies like Takeda Pharmaceutical, Daiichi Sankyo, and Chugai Pharmaceutical being major global players.  Pharmaceutical imports to Japan Despite being one of the biggest medical producers in the world, Japan also relies heavily on pharmaceutical imports. As of 2022, Europe was Japan’s largest supplier of medical drugs, accounting for more than two trillion Japanese yen of the overall import value. Germany and the United States are the major countries importing pharmaceuticals, followed by several European countries like Switzerland, France, and Belgium. Japan’s high life expectancy rate and diminishing birth numbers are posing an ongoing challenge to the healthcare system. While the country already spends a relatively low percentage of its GDP on healthcare compared to other industrialized nations, the Japanese government is seeking to contain healthcare expenditure even further. These measures are expected to lead to a downward pricing pressure that will harm the local industry’s growth. However, Japan is set to remain one of the most important destinations for foreign pharmaceutical suppliers due to the continuously high demand by its aging population.

Japan biopharmaceutical market size reached USD 23.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 35.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.56% during 2025-2033. The market is experiencing growth due to several key factors, including an increasing need for customized medicines, the rising incidence of chronic and lifestyle-related illnesses, and rapid advancements in biotechnology, particularly in areas like genetic engineering and recombinant DNA technology.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on indication and class.

In 2019, long-listed products (LLPs) accounted for about 15.5 percent of the Japanese prescription drug market, down from 35.9 percent in 2009. That year, the drug market share of generics in Japan reached about 15.6 percent.

Japan empty capsules market size reached USD 193.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 343.0 Million by 2033, exhibiting a growth rate (CAGR) of 6.6% during 2025-2033. The growing pharmaceutical industry on account of aging regional population and the need for innovative drug delivery methods to encapsulate medications, making them more palatable and easier to administer, is driving the market.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on type, raw material, functionality, therapeutic application, and end user.

Forecast: Pharmaceuticals in Dosage Market Size Value in Japan 2024 - 2028 Discover more data with ReportLinker!

The Report Covers Asia-Pacific Pharmaceutical Packaging Manufacturers, and the Market is Segmented by Material (Plastic, Paper and Paper Board, Glass, and Aluminum Foil), Type (Ampoules, Blister Packs, Plastic Bottles, Syringes, Vials, and IV Fluids), Drug Delivery Mode (Oral Drug Packaging, Injectable Drug Packaging, and Pulmonary Drug Packaging), and Country (India, Japan, China, Australia, and Rest of Asia-Pacific). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

Forecast: Pharmaceuticals in Dosage Market Size Value Per Capita in Japan 2024 - 2028 Discover more data with ReportLinker!

In 2019, the original drugs segment accounted for nearly 63 percent of the Japanese prescription drug market, up from around 48 percent in 2008. That year, the drug market share of generics stood at about 15.6 percent.